Other Mechanisms (catalog index)

This topic page is a miscellaneous-mechanism catalog over the 7 source notes filed under other-mechanisms. The chapter is heterogeneous by design — disparate mechanisms (TREM2, σ1R, TAU, UPS, …) and an omnibus Pipeline-of-PD MOA table that lists every non-α-Syn / non-GBA / non-LRRK2 program in one block — so this page indexes each mechanism rather than telling a single biological story. It does not replace by-photo Markdown; every entry links to a source note or canonical transcription. Where a source carries Uncertain Spans, that uncertainty is preserved here rather than smoothed out.

Overview

The sections/other-mechanisms cluster collects 7 sources that the document files outside the dedicated MOA chapters (GBA / LRRK2 / α-Syn / Parkin / Mitochondria / Inflammation / Lysosome-Autophagy / …). Three sources sit under the 기타 MOA들 (“other MOAs”) nav root and carry stacked Pipeline-of-PD MOA tables that aggregate every neuroprotection / neuronal-survival / immunization / GLP-1 / urate / σ1R / mGluR5 / CK1 / NMDA-PAM / 5HT7 / HGF-MET / α-Syn-ZFP / α-Syn- APP / cell-therapy / GT row in one place (20240722_184340, 20240722_184348, 20240722_184354). The other four are mechanism-specific pages: a TREM2 / Tremor / TRPML1 mixed page that the document leaves with no nav_path (20240722_184539), a TAU / TCP / Timeline page that records NLRP3-TAU program-ops meeting notes and the NLRP3 Boston Jul 18 biomarker-criteria highlights (20240722_183324), an Unmet Needs / UPS page with the UK Biobank G20 PD case-control top differentially expressed proteins, the Port 2021 patient-priority figure set, and the start of the MOA of UPS E1-E2-E3 cycle table (20240722_184553), and a UPS-tail / PTM-wheel / Omics / Cis-Trans / Intracellular-delivery research-methodology page (20240722_184700). Disease-side biology of α-Syn immunization, urate / antioxidant trials, σ1R PET, UPS biomarker assay (TR-FRET / antibody panels), NLRP3 / pyroptosis, TRPML1, MAM / σ1R imaging, and the Pipeline-of- PD program rows is owned by sibling topic pages and is only linked here.

Source Boundary / Delegation

This topic is bounded inside sections/other-mechanisms and does not include sources from sibling sections. The 기타 MOA들 MOA tables and the _184700 UPS-tail / Omics page reference many programs and assays that already have a primary owner elsewhere:

boundary	adjacent material	owned by
α-Syn immunization pipeline (PD01A, PRX002 / Prasinezumab / PASADENA, BIIB054 / SPARK, Lu AF82422, MEDI-1341, ABBV-0805, UB-312, UCB0599) on _184354; TAK-341 row on _184354; ST-502 (Sangamo) syn-targeted ZF transcriptional repressor row on _184340; ANVS401 (Buntanetap / Posiphen) alpha-syn inhibitor row on _184340; aSyn C-term cleavage / aSyn fragment biomarker bullets in the NLRP3 Boston Jul 18 highlights on _183324	α-Synuclein synthesis (Tier 1)	alpha-synuclein · tak-341 · snca-btv-hdo · snca-aso-wave · asyn-propagation-suppressor
GBA Pathway pipeline rows (Venglustat, LTI-291 / BIA 28-6156, PR001) on _184354	GBA-PD pipeline	gba-gcase-modalities · venglustat · pr001
LRRK2 pipeline rows (DNL-201, DNL-151, BIIB-094) on _184354	LRRK2 pipeline	lrrk2 · lrrk2
NLRP3 / pyroptosis program-ops, NLRP3 inhibitor SharePoint URLs, NLRP3 Boston Jul 18 must-have biomarker criteria, and the AD p-tau / cytokine biomarker bullets on _183324; the inflammatory-marker sub-table inside the ANVS401 row on _184340 (Complement C3 / YKL40 / sTREM2 / GFAp)	inflammation / NLRP3 / pyroptosis program	inflammation · nlrp3-inhibitor
TRPML1 / MCOLN1 lower-page biology (lysosomal Ca²⁺ release → calcineurin → TFEB → autophagy) on _184539	lysosome / autophagy biology	lysosome-autophagy
ROS / screening upper-page continuation (Sirt3 / SDHB; mitochondrial ROS inhibitor; off-pathway antioxidant compounds) on _184539	mitochondrial ROS / assay-side	mitochondria · molecular-biology
Reference-range / UPS schematic / Parkin E3 Ligase TR-FRET kit / polyubiquitin antibody-comparison detection methods on _184557 and _184626	UPS biomarker assay (validation / TR-FRET / TUBE / antibody comparison)	biomarkers-outcomes § Synaptic Biomarkers, SV2A, Surrogate Endpoint, UPS · molecular-biology
σ1R PET biomarker page (SCOPA-AUT > Shipment > Sigma-1 Receptor (σ1R) > σ1R PET > SILK) on _184503; σ1R / MAM imaging on the Structure of mitochondria page	σ1R PET tracer / SILK biomarker / MAM imaging	biomarkers-outcomes · mitochondria · pet-imaging
Pipeline-of-PD overview comparator inventory; LRRK2-PD vs iPD eligibility distinctions; Selegiline / Inosine / DATATOP / PRECEPT / ADAGIO / LS1 historical Phase III disease-modifying trials reference (Biglan 2017 #1563) on _184354	Pipeline-of-PD overview, prodromal / clinical-trial design context	clinical-pd
[BIOMARKER] validation framework, plasma-vs-blood / serum / CSF analyte selection, MDS-UPDRS / DATScan / VMAT outcome measures referenced by the urate (Inosine SURE-PD3 / SURE-PD), MoCA / CDR-SB endpoints, and the UPS / TR-FRET reference-range page	biomarker validation and outcome measures	biomarkers-outcomes
Genomics / Transcriptomics / Proteomics / Metabolomics merit-and-caveat comparison and the UK Biobank G20 PD case-control top differentially expressed protein list (ITGAV, BAG3, HPGDS, CLEC10A, ITGAM, ITGA11, NEFL, CD276, EBI3_IL27, DDC, NCAM1, PSG1) on _184553–_184700; PRS / Results-of-PRS continuation context	omics methodology, proteomics, PRS / GWAS catalog	molecular-biology · genetics-pathway
Pipeline-of-PD program-routing rows for non-α-Syn / non-GBA / non-LRRK2 programs (Tavapadon, pioglitazone, CDNF / HERANTIS, ANVS401, GLP-1 / Exenatide, KW-6356, Pirepemat, SAGE-718, NYX-458, ATH-1017, ALX-001, BIIB118, Selegiline, Inosine, AL002, EPI-589, DA-9805, Deferiprone DR, Tasigna / Nilotinib, K0706, ATV:TREM2 / TREM2-activating small molecule, etc.)	program-routing map	therapeutic-programs § Entity Backlog Candidates

The topic also does not include the Pipeline of PD section’s own sources (filed in sections/clinical-pd), the Pipeline of GD & GBA-PD chapter, the Pipeline of Inflammation / NLRP3 / Pyroptosis chapter, the Pipeline of LRRK2 chapter, the Pipeline MSA chapter, or the Synaptic change in PD page (20240722_184626) — even though those pages re-use the same compound / endpoint vocabulary.

Source Coverage

7 source notes are assigned to the other-mechanisms section. They sit across 5 first-level nav_path clusters; the catalog entries below collapse those clusters as follows:

nav root (first nav_path entry)	sources	covered axis
기타 MOA들	3	Pipeline-of-PD MOA omnibus tables (Tavapadon, pioglitazone, CDNF, ST-502, ANVS401, GLP-1 / Exenatide, KW-6356, Anavex2-73 / σ1R, Pirepemat, SAGE-718, NYX-458, ATH-1017, ALX-001, BIIB118, Selegiline, Inosine), Phase III disease-modifying-trial reference (DATATOP / PRECEPT / QE3 / ADAGIO / LS1), α-Syn immunization pipeline, cross-MoA pipeline by program (Targeting α-Syn / GBA Pathway / LRRK2 / Neuronal Survival / Others)
TAU	1	NLRP3-TAU program ops (SharePoint URLs, Bi-weekly Biomarkers’ / Joint meeting / Timeline / Postmortem stubs); Sleep biomarker block (Zielinski 2017 #2354 SD/LPS → ↑NLRP3 → ↑IL-1b); 202204 NLRP3-TAU meeting notes (aSyn C-term cleavage, tau oligomer-replication Meisl 2021); NLRP3 Boston Jul 18 must-have biomarker criteria; TCP / Timeline / TMQB presenter table; Transfer; Team
Unmet Needs	1	UK Biobank G20 PD case-control top differentially expressed proteins (12 rows: ITGAV, BAG3, HPGDS, CLEC10A, ITGAM, ITGA11, NEFL, CD276, EBI3_IL27, DDC, NCAM1, PSG1); Unmet Needs (Port 2021 #1891 n=790) Fig. 1-4 patient-priority symptom maps; start of MOA of UPS E1-E2-E3 cycle table and 26S proteasome paragraph
UPS	1	UPS impairment in PD patients (table tail with O-GlcNAcylation rows); PTM wheel — Target Protein (5 reversible / irreversible group categories) and Common-PTMs-by-residue frequency table (Phosphorylation 58383 / Acetylation 6751 / O-linked 1133 / Ubiquitylation 878 / …); Metabolomics; Omics merit/caveat (Genomics / Transcriptomics / Proteomics / Metabolomics; Nagaraj 2011, Xu 2012); Temporal & spatial (Body fluids vs Tissue-based); Cis- vs Trans- comparison; Intracellular delivery (transfection / transduction; PTDs from Antp / VP22 / HIV-1 Tat)
(no nav path)	1	TREM2 (R47H / rs75932628-T variant; pathway normal vs mechanism in AD; AL002 / Alector + AbbVie INVOKE-2 P2; AL002c preclinical; ATV:TREM2 / TREM2-activating small molecule rows); Tremor symptom comparison (rest / postural / action-kinetic / essential tremor; cerebellothalamocortical circuit; familial-tremor genetic note); TRPML1 / MCOLN1 lower fragment (delegated); ROS / screening upper continuation (delegated)

For exact nav_path strings and headings see other-mechanisms and the matching by-nav indexes listed in related_topics_by_nav.

Across the 7 sources, source-note frontmatter records 22 uncertain_span_count entries and 0 body-embedded figure assets. The zero-figure-embed count reflects the 2026-04-29 body-purity decision (docs/decisions/2026-04-29-body-purity-and-figure-only-embeds.md): the Pipeline-of-PD MOA tables on _184340 / _184348 / _184354 include CDNF UPDRS-III + DAT-Binding-Potential trajectory crops, the pioglitazone P2 NET-PD efficacy curve, and the ANVS401 inflammatory- marker sub-table; the _183324 page carries cyan / yellow highlight banding on the NLRP3 Boston Jul 18 bullets; the _184539 page is codex-verified-draft mode covering ROS / screening, TREM2 mechanism / agonist-pipeline, Tremor comparison, and TRPML1 lower fragment; the _184553 page carries the Port 2021 #1891 Fig. 1-4 patient-priority panels (Fig. 1 priority bar chart, Fig. 2 tree-map by disease- duration sub-panels, Fig. 3 / Fig. 4 small-multiples bar charts) and the start of the E1-E2-E3 + Substrate ubiquitin diagram; the _184700 page carries the PTM wheel target-protein graphic and the Omics / Cis-Trans / Intracellular-delivery table crops — all kept as evidence rather than embedded. The 22 uncertain spans are retained as review targets and not resolved here.

Mechanism Index

Each entry below names a mechanism (or coherent block) that actually appears in one of the 7 sources, anchors it on a canonical-by-photo link, and records what the page contributes at axis level. Disease- side application of each mechanism (program biology, biomarker grading, GT vehicle, clinical comparator placement) is delegated per the boundary table above. This section does not narrate a unified story across the seven mechanisms and does not re-quote table cells, dose values, or trial-criteria text from the canonical pages.

The section’s README description lists TDP43, TMEM, TRAP1, and PGRN alongside TREM2 / TAU / UPS as example mechanisms. None of those four tokens appears in the nav_path, source_headings, or visible body of the 7 sources assigned to sections/other-mechanisms (TDP43 / TRAP1 / PGRN do not appear at all; TMEM-family genes — TMEM175, TMEM106B — are referenced from the lysosome / autophagy ion-transporter matrix on _183416, which is filed under sections/lysosome-autophagy and is delegated to lysosome-autophagy). They are therefore not promoted to mechanism entries here.

TREM2 — Pathway, R47H, AL002 Pipeline

20240722_184539 carries the TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) chapter across Pathway normal, Mechanism in AD (with the rare missense rs75932628-T → R47H variant row), Genotype-phenotype correlation of TREM2, and a pipeline of TREM2 agonists table covering AL002 / Alector + AbbVie (P2 INVOKE-2 antibody), AL002 Phase 1 healthy-volunteer CSF target engagement (sTREM2 / sCSF-1R), an AL002c preclinical row, and lower TREM2-activating small-molecule / Denali / ATV:TREM2 rows that are mostly blank or cut. Source-side note flags arrow direction, cytokine names (IL-6 / MIP-1a), mutation names, dates, trial criteria, and endpoint labels as manual-review items. The 20240722_184340 ANVS401 row carries an inflammatory-marker sub-table whose rows include sTREM2 alongside Complement C3 / YKL40 / GFAp; that block sits inside the ANVS401 program row and is not a TREM2-program row. 6 Uncertain Spans on _184539 and 2 on _184340. AL002 / ATV:TREM2 / TREM2-activating-small-molecule program-side coverage remains an Entity Backlog Candidate per therapeutic-programs.

Sigma-1 Receptor (σ1R / SIGMAR1) — Anavex2-73 / Blarcamesine

20240722_184348 carries an Anavex2-73 (blarcamesine), activator of SIGMAR1 (=sigma-1 receptor) row (Anavex Life Sciences; ANAVEX 2-73-PDD-001 / NCT03774459 in PDD; oral) with a [Results, 20210702] block covering MDS-UPDRS Total / Part III, SIGMAR1 mRNA biomarker correlation with CoA / MDS-UPDRS endpoints, and an earlier CTAD 2020 AD cognitive-outcome (CDR Episodic Memory / calculated corresponding ADAS-Cog) cross-reference. Specific dose, score, correlation-coefficient, and p-value cells live on the canonical page. 2 Uncertain Spans on the page (KW-6356 top-edge CI clip; Ascherio 2009 column captions). σ1R PET tracer / SILK biomarker page (_184503) and the σ1R / MAM imaging block on the Structure of mitochondria page are delegated per the boundary table.

TAU / NLRP3-TAU Program Operations

20240722_183324 has nav_path TAU > TCP > Timeline but the page body is mostly NLRP3- inhibitor program operations: SharePoint / Teams URLs (NLRP3 Inflammasome Core Team Meetings, Bi-weekly Biomarkers’ Meeting, Joint meeting, Timeline / CN-candidate / Translational-biomarker folders); a Sleep block reproducing a Zielinski 2017 #2354 PD- sleep / NLRP3 grid; a TAU block with a 202204 Nlrp3 meeting with tau bullet list and the cyan-banded NLRP3 Boston, Jul 18 must-have / nice-to-have biomarker-criteria highlights (Overall / aSyn fragment / assay / AD / [MP] PD / AD sub-blocks); followed by TCP, Timeline, a TMQB presenter schedule, Transfer, and Team operational stubs. Specific bullet text, SharePoint URLs, presenter names / times, and Korean inline asides are kept on the canonical page rather than re-quoted here. 4 Uncertain Spans (Sleep header row mostly blank; TMQB list leading-character clip; TAU NLRP3 Boston bullet markers; Transfer leftmost cells n / oo). NLRP3 program biology and the AD p-tau / cytokine / aSyn-fragment biomarker bullets are delegated per the boundary table.

UPS — MOA, PTM Wheel, O-GlcNAcylation, Omics

20240722_184553 opens the MOA of UPS chapter with the E1 → E2 → E3 → poly-Ub → 26S proteasome cycle (E1 ATP-dependent activation; thioester transfer to E2; E3-ligase substrate recognition with ubiquitin transfer to a substrate-protein lysine; poly-Ub-chain formation; 26S proteasome 20S-core / 19S-cap composition; references Tsai 2014, McNaught et al. 2001). Page-tail 20240722_184700 continues with the UPS impairment in PD patients table tail (O-GlcNAcylation rows; positioning vs aSyn-targeting agents; symptomatic-drug-via-synapse cell), the PTM wheel — Target Protein graphic (5 group categories — irreversible amino-acid modification, irreversible cleavage, reversible polypeptide addition, reversible complex-molecule addition, reversible chemical-group addition) feeding a central Target Protein, a Common-PTMs-by-residue frequency table, an Omics merit / caveat comparison (Genomics / Transcriptomics / Proteomics / Metabolomics; Nagaraj 2011, Xu 2012), Temporal & spatial (Body fluids vs Tissue-based), Cis- vs Trans-, and the start of an Intracellular delivery (transfection / transduction; PTDs from Antennapedia / VP22 / HIV-1 Tat) table. Specific frequency-table values, dose / percent-correlation cells, and individual gene-level Cis-Trans descriptions stay on the canonical pages. 4 + 1 = 5 Uncertain Spans across the two pages. UPS / TR-FRET / TUBE biomarker assay biology on _184557 and _184626 is delegated per the boundary table.

Pipeline-of-PD MOA — Compound Omnibus

The 기타 MOA들 cluster carries three stacked Pipeline-of-PD MOA photos that act as the document’s catch-all program inventory for non-α-Syn / non-GBA / non-LRRK2 mechanisms. The catalog below names each row that the canonical pages list (with its mechanism keyword in parentheses); per-row trial / dose / endpoint cells stay on the canonical pages. Program-side coverage is delegated to therapeutic-programs (Entity Backlog Candidates).

• 20240722_184340 — Tavapadon (D1/D5 partial agonist), pioglitazone (PPAR-γ), CDNF / HERANTIS (cerebral dopamine neurotrophic factor; UPR / IRE1 / PERK / ATF6 / GRP78), ST-502 / Sangamo (syn-targeted ZF transcriptional repressor), ANVS401 / Buntanetap / Posiphen by Annovis Bio (β-amyloid precursor protein, alpha-syn inhibitor; carries an inflammatory-marker sub-table), GLP-1 agonists / Exenatide (Byetta, Bydureon; McFarthing 2020 #1342 review), GT, Cell therapy, Inflammation rows. 2 Uncertain Spans.
• 20240722_184348 — KW-6356 top fragment, Anavex2-73 / blarcamesine (σ1R / SIGMAR1 activator; covered separately above), Pirepemat / IRL-752 (5HT7
  • α-2 antagonist), SAGE-718, NYX-458 / Aptinyx (NMDA receptor positive allosteric modulator), ATH-1017 / Athira / fosgonimeton (HGF / MET), ALX-001 / Allyx Tx (silent allosteric modulator of mGluR5), BIIB118 / Casein kinase 1 inhibitor (CK1; circadian- rhythm regulator), Selegiline / Deprenyl + tocopherol (DATATOP P3, Ward 1994 #666), and Inosine / urate (SURE-PD3 NCT02642393, SURE-PD NCT00833690; PRECEPT Schwarzschild 2008 #663 and Ascherio 2009 #664 baseline-serum-urate vs UPDRS- progression / DATScan-change reference tables). 2 Uncertain Spans.
• 20240722_184354 — three stacked summary tables: a Biglan 2017 #1563 Phase-III- disease-modifying-trials reference table (DATATOP, PRECEPT, QE3, ADAGIO, LS1; delegated to clinical-pd); a wide cross-program pipeline overview spanning Targeting α-Syn (Prasinezumab, BIIB-054, TAK-341, Lu AF82422, ABBV-0805, UB-312, UCB0599) / GBA Pathway (Venglustat, LTI-291, PR001) / Targeting LRRK2 (DNL-201, DNL-151, BIIB-094) / Neuronal Survival (EPI-589, DA-9805, Deferiprone DR) / Others (Tasigna / Nilotinib, K0706); and an Active vs Passive α-syn immunization summary covering PD01A / Affiris, PRX002 / Prasinezumab PASADENA, BIIB054 / SPARK, Lu AF82422, MEDI-1341, plus an Inosine / SURE-PD3 row. α-Syn immunization rows are delegated to alpha-synuclein and the α-Syn- program entity pages; GBA Pathway and LRRK2 rows are delegated per the boundary table. 3 Uncertain Spans (right-edge launch- column crops; PD01A stacked-NCT reference cell; Inosine SURE- PD3 dose cell trailing ellipsis).

Tremor Symptom Comparison

20240722_184539 carries a Tremor comparison table spanning Rest tremor, Postural tremor, Action or kinetic tremor, and Essential tremor columns, with clinical-feature cells, an essential-tremor cause cell flagging a 50%: genetic mutation (autosomal dominant): 'familial tremor' note, and a pathophysiology row pointing at cerebellum / cerebellothalamocortical-circuit oscillation with Purkinje-cell- loss / histological-abnormality references whose citation numbers are flagged as high-risk. Symptom-side / clinical-pd disease-side framing of tremor as a PD motor-symptom cluster is delegated to clinical-pd (Pipeline-of-PD comparator inventory; patient-priority symptom set on _184553).

Unmet Needs / UK Biobank G20 PD Proteomics

20240722_184553 opens with the bottom 12 rows of the UK Biobank — Top differentially expressed and decreased proteins for G20 Parkinson's Disease Case- Control analysis table (Direction / GeneName / Protein / Function / OR / P columns; gene set ITGAV, BAG3, HPGDS, CLEC10A, ITGAM, ITGA11, NEFL, CD276, EBI3_IL27, DDC, NCAM1, PSG1; per-row OR / P / function cells stay on the canonical page). The Unmet Needs section reproduces Port 2021 #1891 (n = 790; 86% patients) Fig. 1-4 patient- priority symptom maps — Fig. 1 priority bar chart, Fig. 2 disease- duration tree-map, Fig. 3 (priority-decreasing-with-duration: tremor / stiffness / psychological-health), Fig. 4 (priority- increasing-with-duration: balance & falls, walking, speech, freezing, dyskinesia, medication-wearing-off) — and an Overall red Korean note that ranks the dominant priorities and trails off at pain (cogniti (closing parenthesis cropped). 4 Uncertain Spans. UK Biobank G20 proteomic-catalog application is delegated to molecular-biology and biomarkers-outcomes; patient-priority symptom-map context for clinical-PD comparator inventory is owned by clinical-pd.

TRPML1 / ROS-Screening Fragments (Boundary)

20240722_184539 also carries (i) an upper continuation of a ROS / screening table from the previous photo and (ii) a TRPML1 / MCOLN1 lower section (lysosomal Ca²⁺-permeable channel; MTORC1 / CAMKK2-AMPK / TFEB nuclear-translocation chain; red therapeutic-strategy line; Korean note flagging the channel as a lysosomal iron-trafficking channel per (Misko)). Both blocks are listed here for catalog completeness; the ROS / screening biology is owned by mitochondria / molecular-biology and the TRPML1 / MCOLN1 biology is owned by lysosome-autophagy (which carries the upstream _184542 TRPML1 page). They are not re-narrated here.

Source Table

All 7 sources, in capture-time order, with the per-page uncertain- span and embedded-image counts copied verbatim from source-note quality_metrics. nav path is the full nav_path recorded in the source note (joined by >).

stem	nav path / heading	source note	canonical	uncertain spans	embedded images
20240722_183324	TAU > TCP > Timeline	note	md	4	0
20240722_184340	기타 MOA들	note	md	2	0
20240722_184348	기타 MOA들	note	md	2	0
20240722_184354	기타 MOA들	note	md	3	0
20240722_184539	(no nav path)	note	md	6	0
20240722_184553	Unmet Needs > UPS > MOA of UPS	note	md	4	0
20240722_184700	UPS > Metabolomics > Omics > Cis- vs Trans- > Intracellular delivery	note	md	1	0

Totals across the 7 sources: uncertain_span_count = 22, embedded_image_count = 0. These are review surface area; the zero-figure-embed count reflects the 2026-04-29 body-purity decision (docs/decisions/2026-04-29-body-purity-and-figure-only-embeds.md) under which mixed text-and-figure crops on these pages (CDNF UPDRS- III curve, pioglitazone NET-PD efficacy curve, ANVS401 inflammatory- marker sub-table, NLRP3 Boston Jul 18 cyan-banded bullets, Port 2021 #1891 Fig. 1-4 patient-priority panels, PTM wheel target- protein graphic) are kept as evidence rather than embedded.

Uncertainties Carried Forward

This page does not paraphrase Pipeline-of-PD MOA / Phase-III-trial / α-Syn-immunization / UK-Biobank-OR-P / Port-2021-figure / MOA-of-UPS / PTM-frequency / Omics-merit-caveat / Cis-Trans / Intracellular- delivery / TREM2-AD-mechanism / Tremor / NLRP3-Boston-Jul-18 cells. Specific uncertainty hot spots worth checking before any downstream extraction:

• Pipeline-of-PD MOA tables on _184340 (CDNF 9off) token; ANVS401 inflammatory-marker p-value column right-edge crop) and _184348 (KW-6356 top-edge CI lower-bound clip; Ascherio 2009 column captions inferred from the analogous PRECEPT table; row order continues past the visible body area) — 2 + 2 spans.
• Pipeline-by-MoA cross-program table on _184354 — right-most Est. Launch (US) column partially cut (Q3 20... / 2027+ preserved as printed); PD01A reference cell stacked NCT identifiers and [15] citation; Inosine SURE-PD3 dose cell trails off as Up to 3 g/day, titrated to ... — 3 spans.
• TREM2 / Tremor / TRPML1 mixed page _184539 (in codex_verified_draft mode) — dense tables, arrows, mutation names, cytokines, citation numbers, Greek letters, Ca²⁺ / β symbols, contact / URL strings, and Korean notes flagged for manual image verification — 6 spans.
• TAU / NLRP3-TAU page _183324 — Sleep header row mostly blank; TMQB list leading-character crop; NLRP3 Boston Jul 18 dash / bullet marker variation; Transfer leftmost cells n / oo partially cut; long SharePoint / Teams URLs preserved verbatim — 4 spans.
• Unmet Needs / UK Biobank page _184553 — OR / P column micro- text; Fig. 1 / Fig. 2 caption sample-size cells; the Korean Overall red note tail pain (cogniti with closing parenthesis cropped — 4 spans.
• UPS / PTM / Omics / Cis-Trans / Intracellular-delivery page _184700 — Intracellular-delivery left-column truncated tokens (e, ein, over, ? cut at the page edge) — 1 span.

Related Pages

• other-mechanisms — section index for all 7 sources
• alpha-synuclein — sibling topic (Tier 1); owns α-Syn immunization pipeline (PD01A, Prasinezumab / PASADENA, BIIB054 / SPARK, Lu AF82422, MEDI-1341, ABBV-0805, UB-312, UCB0599), TAK-341 row, ST-502 / Sangamo ZF transcriptional repressor, ANVS401 / Buntanetap alpha-syn inhibitor row, and the aSyn C-term cleavage / aSyn fragment biomarker bullets
• tak-341 / snca-btv-hdo / snca-aso-wave / asyn-propagation-suppressor — own α-Syn-targeting program rows referenced in the Pipeline-by-MoA cross-program table on _184354
• gba-gcase-modalities / venglustat / pr001 — own GBA Pathway pipeline rows (Venglustat, LTI-291 / BIA 28-6156, PR001) referenced on _184354
• lrrk2 / lrrk2 — own LRRK2 pipeline rows (DNL-201, DNL-151, BIIB-094) referenced on _184354
• inflammation / nlrp3-inhibitor — own NLRP3 / pyroptosis program biology, NLRP3 inhibitor program-ops bundle on _183324, NLRP3 Boston Jul 18 must-have / nice-to-have biomarker criteria, AD p-tau / cytokine biomarker bullets, and the inflammatory-marker sub-table inside the ANVS401 row on _184340
• lysosome-autophagy — owns TRPML1 / MCOLN1 lysosomal Ca²⁺-release / TFEB / autophagy / lysosomal-biogenesis biology that the _184539 lower fragment underwrites
• mitochondria / molecular-biology — own ROS / screening / mitochondrial ROS-inhibitor assay-side biology that the _184539 upper continuation underwrites; molecular-biology also owns the Genomics / Transcriptomics / Proteomics / Metabolomics merit-and-caveat methodology and the UK Biobank G20 proteomic-catalog post-translational-modification context
• biomarkers-outcomes — owns the UPS / TR-FRET / TUBE Reference-range page (_184557), the Synaptic-change-in-PD page (_184626), the σ1R PET / SILK biomarker page (_184503), and the [BIOMARKER] validation framework / plasma-vs-blood / serum / CSF analyte-selection / MDS-UPDRS / DATScan / VMAT outcome-measure context that the urate (Inosine SURE-PD3 / SURE-PD), MoCA / CDR-SB endpoints, and AL002 / sTREM2 / sCSF-1R target-engagement biomarkers depend on
• clinical-pd — owns Pipeline-of-PD overview, prodromal / clinical-trial design, comparator inventory, LRRK2-PD vs iPD eligibility, and DATATOP / PRECEPT / QE3 / ADAGIO / LS1 historical Phase III disease-modifying-trial reference framing; patient-priority symptom maps from Port 2021 #1891 also support clinical-PD comparator inventory
• genetics-pathway — owns PRS / Results-of-PRS / GWAS / pathway-analysis methodology that the _184700 Genomics / Transcriptomics caveats and the UK Biobank G20 case-control proteomic-catalog feed
• pet-imaging — owns σ1R PET tracer development that the Anavex2-73 / SIGMAR1 mRNA biomarker references
• therapeutic-programs — program-routing map; non-α-Syn / non-GBA / non-LRRK2 Pipeline-of-PD MOA rows (Tavapadon, pioglitazone, CDNF / HERANTIS, ANVS401, GLP-1 / Exenatide, KW-6356, Pirepemat, SAGE-718, NYX-458, ATH-1017, ALX-001, BIIB118, Selegiline, Inosine, AL002, EPI-589, DA-9805, Deferiprone DR, Tasigna / Nilotinib, K0706, ATV:TREM2 / TREM2-activating small molecule) are not promoted to entity pages in v1 and remain Entity Backlog Candidates here
• 기타-moa들 — 기타 MOA들 first-nav_path index
• tau — TAU first-nav_path index
• ups — UPS first-nav_path index
• unmet-needs — Unmet Needs first-nav_path index
• unclassified — sources whose nav_path is empty (includes _184539)
• source-catalog — all 447 sources in capture order
• nav-path-index — 376 distinct nav_paths